Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-LNC1004
- Development stage
- Unknown
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[177Lu]Lu-LNC1004 is an investigational radioligand therapy consisting of a fibroblast activation protein inhibitor (FAPI) small molecule conjugated to the beta-emitting radionuclide lutetium-177 via a DOTA chelator, and modified with Evans blue (EB) to enhance albumin binding, thereby prolonging blood circulation and tumor retention. Developed by Yantai Lannacheng Biotechnology (a subsidiary of Dongcheng Pharmaceutical), the drug targets fibroblast activation protein (FAP) overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment. It is being evaluated in clinical trials for the treatment of advanced FAP-positive solid tumors, including radioiodine-refractory differentiated thyroid cancer.
- Other names
- 177Lu-DOTA-EB-FAPI177Lu-EB-FAPI177Lu-Evans blue-FAP inhibitorlutetium Lu 177 LNC1004
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on [177Lu]Lu-LNC1004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-LNC1004.